JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PWOD
6276
DELISTED
Penns Woods Bancorp
PWOD
| $1K | ﹤0.01% |
+40
| New | +$1.04K |
2023 Q1
0 quarters
|
|
6277
Quince Therapeutics
QNCX
$29.7M
| $1K | ﹤0.01% |
2
| – | – |
2019 Q2
15 quarters
|
|
6278
ProShares Short Real Estate
REK
$12.6M
| $1K | ﹤0.01% |
46
-2,606
| -98% | -$51.1K |
2022 Q2
3 quarters
|
|
6279
Riverview Bancorp
RVSB
$120M
| $1K | ﹤0.01% |
+141
| New | +$960 |
2023 Q1
0 quarters
|
|
6280
Royce Value Trust
RVT
$2.15B
| $1K | ﹤0.01% |
89
-4,151
| -98% | -$58.2K |
2022 Q2
3 quarters
|
|
6281
Invesco S&P SmallCap 600 Pure Value ETF
RZV
$281M
| $1K | ﹤0.01% |
+9
| New | +$864 |
2023 Q1
0 quarters
|
|
6282
SB Financial Group
SBFG
$184M
| $1K | ﹤0.01% |
91
+79
| +658% | +$1.26K |
2020 Q2
11 quarters
|
|
|
SBR
6283
Sabine Royalty Trust
SBR
$1.03B
| $1K | ﹤0.01% |
+7
| New | +$551 |
2023 Q1
0 quarters
|
|
6284
Companhia Siderúrgica Nacional
SID
$1.54B
| $1K | ﹤0.01% |
292
-194,511
| -100% | -$628K |
2022 Q3
2 quarters
|
|
6285
Solid Biosciences
SLDB
$734M
| $1K | ﹤0.01% |
133
| – | – |
2018 Q1
20 quarters
|
|
|
SNCR
6286
DELISTED
Synchronoss Technologies
SNCR
| $1K | ﹤0.01% |
107
| – | – |
2018 Q4
17 quarters
|
|
6287
Sonoma Pharmaceuticals
SNOA
$5.94M
| $1K | ﹤0.01% |
+34
| New | +$876 |
2023 Q1
0 quarters
|
|
|
FTH
6288
Faeth Therapeutics
FTH
$733M
| $1K | ﹤0.01% |
33
| – | – |
2021 Q1
8 quarters
|
|
6289
PUT
SoFi Technologies
SOFI
$20.4B
| $1K | ﹤0.01% |
+100
| New | +$606 |
2023 Q1
0 quarters
|
|
6290
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
$7.43B
| $1K | ﹤0.01% |
42
-16,000
| -100% | -$464K |
2021 Q3
6 quarters
|
|
6291
Northern Trust iBoxx 3-Year Target Duration TIPS ETF
TDTT
$2.49B
| $1K | ﹤0.01% |
+23
| New | +$546 |
2023 Q1
0 quarters
|
|
6292
Tempest Therapeutics
TPST
$13.7M
| $1K | ﹤0.01% |
+24
| New | +$526 |
2023 Q1
0 quarters
|
|
6293
ReposiTrak
TRAK
$147M
| $1K | ﹤0.01% |
183
+163
| +815% | +$971 |
2020 Q2
11 quarters
|
|
6294
Taysha Gene Therapies
TSHA
$1.51B
| $1K | ﹤0.01% |
1,782
| – | – |
2020 Q4
9 quarters
|
|
6295
AgEagle Aerial Systems
UAVS
$60.2M
| $1K | ﹤0.01% |
1
| – | – |
2021 Q2
7 quarters
|
|
6296
Telefônica Brasil
VIV
$18.4B
| $1K | ﹤0.01% |
193
-1,051,394
| -100% | -$7.9M |
2022 Q2
3 quarters
|
|
6297
Invesco Trust for Investment Grade New York Municipals
VTN
$141M
| $1K | ﹤0.01% |
+83
| New | +$862 |
2023 Q1
0 quarters
|
|
6298
Arq
ARQ
$84.7M
| $1K | ﹤0.01% |
303
-6,223
| -95% | -$16.9K |
2017 Q2
23 quarters
|
|
|
QCLS
6299
Q/C Technologies Inc
QCLS
$6.13M
| – | – |
0
| – | – |
2023 Q1
0 quarters
|
|
|
GRCE
6300
Grace Therapeutics
GRCE
$43.5M
| $1K | ﹤0.01% |
+208
| New | +$743 |
2023 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.